7b, a novel naphthalimide derivative exhibited anti-inflammatory effects via targeted-inhibiting TAK1 following down-regulation of ERK1/2- and p38 MAPK-mediated activation of NF-κB in LPS-stimulated RAW264.7 macrophages

International Immunopharmacology

Volumn 17, Issue 2, 2013, Pages 216-228

  Shao, Jin ^a   Li, Yiquan ^a   Wang, Ziyuan ^a   Xiao, Mengmeng ^a   Yin, Peihao ^b   Lu, Yanhua ^a   Qian, Xuhong ^a   Xu, Yufang ^a   Liu, Jianwen ^a  

^a EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

7b; Anti inflammatory; MAPK; NF B; TAK1

Indexed keywords

6 (DODECYLAMINO) 2 (3 (4 METHYLPIPERAZIN 1 YL)PROPYL) 1H BENZO [DE]ISOQUINOLINE 1,3(2H) DIONE; ANTIINFLAMMATORY AGENT; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 14; MITOGEN ACTIVATED PROTEIN KINASE 3; NAPHTHALIMIDE DERIVATIVE; NITRIC OXIDE; PROSTAGLANDIN E2; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DOWN REGULATION; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; MACROPHAGE; MALE; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

7B; ANTI-INFLAMMATORY; MAPK; NF-ΚB; TAK1;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL LINE; CYCLOOXYGENASE 2; DINOPROSTONE; DOWN-REGULATION; LIPOPOLYSACCHARIDES; MACROPHAGES, PERITONEAL; MALE; MAP KINASE KINASE KINASES; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED C57BL; MOLECULAR TARGETED THERAPY; NAPHTHALIMIDES; NF-KAPPA B; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PIPERAZINES; TRANSCRIPTIONAL ACTIVATION;

EID: 84881515075     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2013.06.008     Document Type: Article

References (53)

1. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140:883-99.
2. Lin W-W, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 2007;117:1175-83. (Pubitemid 46718402)
3. Ingrassia L, Lefranc F, Kiss R, Mijatovic T. Naphthalimides and azonafides as promising anti-cancer agents. Curr Med Chem 2009;16:1192-213.
4. Cavigiolio G, Morgan JL, Robinson BH, Simpson J. Fluorescent sugar and uridine conjugates of 1,8-naphthalimides with methyl and ferrocenyl headgroups. Aust J Chem 2004;57:885-94.
5. Chen Z, Liang X, Zhang HY, Xie H, Liu JW, Xu YF, et al. A new class of naphthalimide-based antitumor agents that inhibit topoisomerase ii and induce lysosomal membrane permeabilization and apoptosis. J Med Chem 2010;53:2589-600.
6. Lin B, Chen Z, Xu Y, Zhang H, Liu J, Qian X. 7-b, a novel amonafide analogue, cause growth inhibition and apoptosis in Raji cells via a ROS-mediated mitochondrial pathway. Leuk Res 2011;35:646-56.
7. Shao J, Li Y, Shen K, Lin B, Xu Y, Lu Y, et al. 7b, a novel amonafide analog, inhibited proliferation and phorbol 12-myristate 13-acetate/ phytohemagglutinin-induced inflammatory responses of Jurkat T cells via p73-dependent pathway and decrease of nuclear factor-kappaB DNA-binding, respectively. Leuk Lymphoma 2013;54:359-71.
8. Aid S, Bosetti F. Targeting cyclooxygenases-1 and -2 in neuroinflammation: therapeutic implications. Biochimie 2011;93:46-51.
9. Dinarello CA. Anti-inflammatory agents: present and future. Cell 2010;140:935-50.
10. Rahman A, Yatsuzuka R, Jiang S, Ueda Y, Kamei C. Involvement of cyclooxygenase-2 in allergic nasal inflammation in rats. Int Immunopharmacol 2006;6:1736-42.
11. Pereira RD. Selective cyclooxygenase-2 (COX-2) inhibitors used for preventing or regressing cancer. Recent Pat Anticancer Drug Discov 2009;4:157-63.
12. Sarkar FH, Adsule S, Li Y, Padhye S. Back to the future: COX-2 inhibitors for chemoprevention and cancer therapy. Mini Rev Med Chem 2007;7:599-608. (Pubitemid 47099180)
13. Tsatsanis C, Androulidaki A, Venihaki M, Margioris AN. Signalling networks regulating cyclooxygenase-2. Int J Biochem Cell Biol 2006;38:1654-61. (Pubitemid 43947653)
14. Gao YT, Panda SP, Roman LJ, Martasek P, Ishimura Y, Masters BS. Oxygen metabolism by neuronal nitric-oxide synthase. J Biol Chem 2007;282:7921-9. (Pubitemid 47093572)
15. Nathan C, Xie QW. Nitric oxide synthases: roles, tolls, and controls. Cell 1994;78:915-8. (Pubitemid 24292319)
16. Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthases: structure, function and inhibition. Biochem J 2001;357:593-615. (Pubitemid 32735142)
17. Marletta MA. Nitric oxide synthase structure and mechanism. J Biol Chem 1993;268:12231-4. (Pubitemid 23182366)
18. MacMicking J, Xie QW, Nathan C. Nitric oxide and macrophage function. Annu Rev Immunol 1997;15:323-50. (Pubitemid 27169284)
19. Maeda H, Akaike T. Nitric oxide and oxygen radicals in infection, inflammation, and cancer. Biochemistry (Mosc) 1998;63:854-65. (Pubitemid 128588115)
20. Fukumura D, Kashiwagi S, Jain RK. The role of nitric oxide in tumour progression. Nat Rev Cancer 2006;6:521-34. (Pubitemid 43980541)
21. Hayden MS, Ghosh S. Shared principles in NF-kappaB signaling. Cell 2008;132: 344-62.
22. Cho E-J, An H-J, Shin J-S, Choi H-E, Ko J, Cho Y-W, et al. Roxatidine suppresses inflammatory responses via inhibition of NF-κB and p38 MAPK activation in LPS-induced RAW 264.7 macrophages. J Cell Biochem 2011;112:3648-59.
23. Blonska M, Lin X. NF-[kappa]B signaling pathways regulated by CARMA family of scaffold proteins. Cell Res 2011;21:55-70.
24. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 2000;18:621-63. (Pubitemid 30365393)
25. Xie QW, Kashiwabara Y, Nathan C. Role of transcription factor NF-kappa B/Rel in induction of nitric oxide synthase. J Biol Chem 1994;269:4705-8. (Pubitemid 24239438)
26. Hla T, Ristimaki A, Appleby S, Barriocanal JG. Cyclooxygenase gene expression in inflammation and angiogenesis. Ann N Y Acad Sci 1993;696:197-204. (Pubitemid 24062788)
27. Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J Clin Invest 2001;107: 135-42. (Pubitemid 32096826)
28. Guha M, Mackman N. LPS induction of gene expression in human monocytes. Cell Signal 2001;13:85-94. (Pubitemid 32222977)
29. Ahmed KM, Dong S, Fan M, Li JJ. Nuclear factor-kappaB p65 inhibits mitogenactivated protein kinase signaling pathway in radioresistant breast cancer cells. Mol Cancer Res 2006;4:945-55. (Pubitemid 46121553)
30. Jung HS, Yoon BH, Jun JK, Kim M, Kim YA, Kim CJ. Differential activation of mitogen activated protein kinases and nuclear factor-kappaB in lipopolysaccharide-treated term and preterm amnion cells. Virchows Arch 2005;447:45-52. (Pubitemid 41126239)
31. Lee J, Mira-Arbibe L, Ulevitch RJ. TAK1 regulates multiple protein kinase cascades activated by bacterial lipopolysaccharide. J Leukoc Biol 2000;68:909-15.
32. Kishimoto K, Matsumoto K, Ninomiya-Tsuji J. TAK1 mitogen-activated protein kinase kinase kinase is activated by autophosphorylation within its activation loop. J Biol Chem 2000;275:7359-64. (Pubitemid 30146289)
33. Irie T, Muta T, Takeshige K. TAK1 mediates an activation signal from toll-like receptor( s) to nuclear factor-kappaB in lipopolysaccharide-stimulated macrophages. FEBS Lett 2000;467:160-4. (Pubitemid 30081726)
34. Gingery A, Bradley EW, Pederson L, Ruan M, Horwood NJ, Oursler MJ. TGF-beta coordinately activates TAK1/MEK/AKT/NFkB and SMAD pathways to promote osteoclast survival. Exp Cell Res 2008;314:2725-38.
35. Bruni D, Sebastia J, Dunne S, Schroder M, Butler MP. A novel IRAK1-IKKepsilon signaling axis limits the activation of TAK1-IKKbeta downstream of TLR3. J Immunol 2013;190:2844-56.
36. Miyatake K, Inoue H, Hashimoto K, Takaku H, Takata Y, Nakano S, et al. PKC412 (CGP41251) modulates the proliferation and lipopolysaccharide-induced inflammatory responses of RAW 264.7 macrophages. Biochem Biophys Res Commun 2007;360:115-21. (Pubitemid 46990331)
37. Israf DA, Khaizurin TA, Syahida A, Lajis NH, Khozirah S. Cardamonin inhibits COX and iNOS expression via inhibition of p65NF-kappaB nuclear translocation and Ikappa-B phosphorylation in RAW 264.7 macrophage cells. Mol Immunol 2007;44:673-9. (Pubitemid 44415023)
38. Lee AK, Sung SH, Kim YC, Kim SG. Inhibition of lipopolysaccharide- inducible nitric oxide synthase, TNF-alpha and COX-2 expression by sauchinone effects on I-kappaBalpha phosphorylation, C/EBP and AP-1 activation. Br J Pharmacol 2003;139:11-20. (Pubitemid 36645303)
39. Lawrence T. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol 2009;1:a001651.
40. Baeuerle PA, Baltimore D. I kappa B: a specific inhibitor of the NF-kappa B transcription factor. Science 1988;242:540-6. (Pubitemid 18263193)
41. Zandi E, Rothwarf DM, Delhase M, Hayakawa M, Karin M. The IkappaB kinase complex (IKK) contains two kinase subunits, IKKalpha and IKKbeta, necessary for IkappaB phosphorylation and NF-kappaB activation. Cell 1997;91:243-52. (Pubitemid 27456391)
42. Rajapakse N, Kim MM, Mendis E, Kim SK, Rajapakse N, Kim MM, et al. Inhibition of inducible nitric oxide synthase and cyclooxygenase-2 in lipopolysaccharidestimulated RAW264.7 cells by carboxybutyrylated glucosamine takes place via down-regulation of mitogen-activated protein kinase-mediated nuclear factorkappa B signaling. Immunology 2008;123:348-57. (Pubitemid 351171187)
43. Kim JY, Kim HS, Kim YJ, Lee HK, Kim JS, Kang JS, et al. Inhibition of TAK1 by kamebakaurin in dendritic cells. Int Immunopharmacol 2013;15:138-43.
44. Lv M, Xu H. Overview of naphthalimide analogs as anticancer agents. Curr Med Chem 2009;16:4797-813.
45. Philip M, Rowley DA, Schreiber H. Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol 2004;14:433-9. (Pubitemid 39360991)
46. Liu JW, Lin B, Chen Z, Xu YF, Zhang HY, Qian XH. 7-b, a novel amonafide analogue, cause growth inhibition and apoptosis in Raji cells via a ROS-mediated mitochondrial pathway. Leuk Res 2011;35:646-56.
47. Mariathasan S, Monack DM. Inflammasome adaptors and sensors: intracellular regulators of infection and inflammation. Nat Rev Immunol 2007;7:31-40. (Pubitemid 46020825)
48. Heiss E, Herhaus C, Klimo K, Bartsch H, Gerhauser C. Nuclear factor kappa B is a molecular target for sulforaphane-mediated anti-inflammatory mechanisms. J Biol Chem 2001;276:32008-15.
49. Nagano S, Otsuka T, Niiro H, Yamaoka K, Arinobu Y, Ogami E, et al. Molecular mechanisms of lipopolysaccharide?induced cyclooxygenase?2 expression in human neutrophils: involvement of the mitogen?activated protein kinase pathway and regulation by anti?inflammatory cytokines. Int Immunol 2002;14: 733-40. (Pubitemid 34814633)
50. Garcia MA, Gallego P, Campagna M, González-Santamaría J, Martínez G, Marcos-Villar L, et al. Activation of NF-kB pathway by virus infection requires Rb expression. PLoS One 2009;4:e6422.
51. Lawrence T, Gilroy DW, Colville-Nash PR, Willoughby DA. Possible new role for NF-kappaB in the resolution of inflammation. Nat Med 2001;7:1291-7. (Pubitemid 34007932)
52. Kim JE, Kwon JY, Seo SK, Son JE, Jung SK, Min SY, et al. Cyanidin suppresses ultraviolet B-induced COX-2 expression in epidermal cells by targeting MKK4, MEK1, and Raf-1. Biochem Pharmacol 2010;79:1473-82.
53. Schett G, Tohidast-Akrad M, Smolen JS, Schmid BJ, Steiner CW, Bitzan P, et al. Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis. Arthritis Rheum 2000;43:2501-12.